Showing 6961-6970 of 9550 results for "".
- New Acoustic Shockwave Technology May Speed Laser Tattoo Removalhttps://practicaldermatology.com/news/new-acoustic-shockwave-technology-may-speed-laser-tattoo-removal/2457548/Soliton, Inc. is introducing new acoustic shockwave technology for quicker laser tattoo removal. What’s more, the new device also shows potential in aesthetics market for cellulite and fat removal. The patented
- Asana Biosciences Gets Fast Track Designation from FDA for Dual JAK/SYK Inhibitor for ADhttps://practicaldermatology.com/news/asana-biosciences-gets-fast-track-designation-from-fda-for-dual-jaksyk-inhibitor-for-ad/2457550/The FDA has granted Fast Track designation to Asana BioSciences’ investigational oral Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK) dual inhibitor ASN002 for the treatment of moderate-to-severe atopic dermatitis. “We are pleased that the FDA has granted Fast Track
- New PsA Guidelines from National Psoriasis and Rheumatology Orgs Recommend Treat-to-Target Approachhttps://practicaldermatology.com/news/new-psa-guidelines-from-national-psoriasis-and-rheumatology-orgs-recommend-treat-to-target-approach/2457490/Newly released psoriatic Arthritis (PsA) treatment guidelines from the National Psoriasis Foundation (NPF) and the American College of Rheumatology (ACR) are calling for a treat-to-target approach for all patients with active PsA. What’s more, the guidelines co
- Crown Laboratories Acquires Select Healthcare Brands from GlaxoSmithKlinehttps://practicaldermatology.com/news/crown-laboratories-acquires-select-healthcare-brands-from-glaxosmithkline/2457492/Crown Laboratories, Inc. has acquired North American distribution rights of five OTC consumer brands from GlaxoSmithKline (GSK). The acquired portfolio includes: PanOxyl® daily acne wash, Sarna® anti-itch lotion, Zeasorb® anti-fungal and prevention product, De
- Study: Lipid that Aids Normal Skin Turnover May Help Psoriasishttps://practicaldermatology.com/news/study-lipid-that-aids-normal-skin-turnover-may-help-psoriasis/2457495/A lipid that helps keep skin cell turnover on track may help restore healthy turnover in psoriasis, investigators say. Topical application of the lipid phosphatidylglycerol, or PG, on a mouse model of psoriasis reduced inflammation as well as characteristic, raised skin lesions, they report in th
- Nanoparticulate-based Sunscreens May Not Be So Dangerous After Allhttps://practicaldermatology.com/news/nanoparticulate-based-sunscreens-may-not-be-so-dangerous-after-all/2457499/Zinc oxide nanoparticles used in sunscreen neither penetrate the skin nor cause cellular toxicity after repeated applications, according to a study out of University of Queensland (UQ) and University of South Australia, The
- Exuviance Introduces HA100 Micro-Filler Regimenhttps://practicaldermatology.com/news/exuviance-introduces-ha100-micro-filler-regimen/2457502/Exuviance is launching HA100 Micro-Filler Regimen, a two-step beauty regimen featuring new Micro-Cone Patches that delivers 1
- The American Dermatological Association Is On Board with American Cancer Society's HPV Vaccine Policyhttps://practicaldermatology.com/news/the-american-dermatological-association-is-on-board-with-american-cancer-societys-hpv-vaccine-policy/2457513/The American Dermatological Association is co-sponsoring the American Cancer Society’s public policy of vaccination against Human Papillomavirus infections [HPV] beginning at age 11 or 12 for girls and boys. HPV is associated with protean medical illne
- US FDA Grants Dupixent Priority Review for Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-grants-dupixent-priority-review-for-moderate-to-severe-ad-in-adolescents/2457517/The US Food and Drug Administration (FDA) has granted Priority Review for Dupixent (dupilumab) as a potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis (AD). Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with m
- FDA Approves Galderma's Restylane Lyft for Midface Injection Via Cannulahttps://practicaldermatology.com/news/fda-approves-galdermas-restylane-lyft-for-midface-injection-via-cannula/2457518/The U.S. Food and Drug Administration (FDA) has approved the use of Galderma’s Restylane Lyft with a small, blunt-tip cannula for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. This approval is the second ca